Seattle Genetics positive data largely as expected, says Piper Jaffray

Seattle Genetics weakness a buying opportunity, says Credit Suisse Credit Suisse said Seattle Genetics top-line AETHERA data was significantly positive for the primary endpoint and expects full results in December at ASH to provide a meaningful update. The firm would use weakness as a buying opportunity and reiterates its Outperform rating and $51 price target.

http://ift.tt/1rycA8e